3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Lymphoma, Follicular
1
Dementia
1
Alzheimer Disease
1
Interventions
XENP 1595
2
birtamimab
1
UE2343
1
Rosiglitazone
1
Propofol
1
Positron-Emission Tomography
1
Methotrexate
1
Electroencephalography
1
Donepezil
1
Blood Specimen Collection
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Alzheimer Disease
×
UE2343
×
Clear all
NCT06125951
2026-04-23
XanaMIA
Actinogen Medical
Phase 2/3
Active not recruiting
247 enrolled